PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Scientists develop microfluidic chip to make cell therapy safer

The chip removes cells, which could become tumours, before they are implanted in a patient.

Researchers from the Massachusetts Institute of Technology (MIT) and the Singapore-MIT Alliance for Research and Technology have developed a plastic microfluidic chip to improve the safety and effectiveness of cell therapy treatments for patients living with spinal cord injuries.

In cell therapy, clinicians create induced pluripotent stem cells using skin or blood cells from a patient.

When treating a spinal cord injury, pluripotent stem cells are transformed into progenitor cells, which differentiate into spinal cord cells, which are transplanted back into the patient.

Despite being able to regenerate part of the injured spinal cord, pluripotent stem cells do not completely change into progenitors and can form tumours.

Researchers developed a microfluidic cell sorter to remove around half of the undifferentiated cells in a batch to mitigate potential tumours without causing damage to fully-formed progenitor cells.

The low-cost plastic chip device sorts over three million cells per minute and when chained with many devices, it can sort more than 500 million cells per minute.

The team found that pluripotent stem cells were larger than the progenitors from which they derived. The microfluidic device works to leverage this size difference to sort the cells.

In addition, researchers also noted that they could improve the sorter’s operation by running it twice: first at a lower speed to stick larger cells to the walls and sort smaller cells out, then at a higher speed to sort out larger cells.

In total, the device could remove around 50% of the larger cells with one pass. Researchers also confirmed that the larger cells they removed were associated with a higher tumour risk.

Researchers now plan to conduct larger studies and animal models to see if the purified cells function better in vivo.

“If we can convincingly demonstrate these benefits in vivo, the future might hold even more exciting applications for this technique,” said Jongyoon Han, MIT professor of electrical engineering and computer science, and biological engineering.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026